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ABSTRACT  
Pemphigus vulgaris (PV) is an autoimmune blistering skin disease characterized by 
suprabasal acantholysis and by autoantibodies against desmoglein 3 localized on 
desmosomes. In addition, caspases also seem to participate in this blistering disease. 
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase involved in 
cytoskeleton remodelling and formation and disassembly of cell adhesion structures. 
We have previously demonstrated that HER (human epidermal growth factor receptor 
related) isoforms, Src (Rous sarcoma) and mammalian target of rapamycin (mTOR), 
three molecules implicated in signalling processes, take part in suprabasal acantholysis 
and apoptosis induced by PV-IgG in a mouse model. Our aim was to investigate 
whether upregulation of FAK is implicated in the development of PV lesions. Herein, 
using a mouse model, PV-IgG administration showed an increased level of FAK 
phosphorylated on 397 and 925 tyrosine residues in the basal layer of epidermis. 
  
When mice were pretreated with a FAK inhibitor (FI), the acantholysis of the basal 
layer of epidermis was absent. More interestingly, we observed that phosphorylated 
FAK (Y397⁄925) decreased when HER isoforms, Src, mTOR and pan-caspases 
inhibitors were employed before PV-IgG administration. In addition, pretreatment with 
the FI before PV-IgG injection prevented the changes in both Bax and Bcl-2 
expression and caspase-9 and caspase-3 activities induced by PV-IgG. Finally, FI 
reduced the expression of phosphorylated Src and mTOR in the basal cells of 
epidermis. In conclusion, our data reveal a novel role of phosphorylated FAK 
(Y397⁄925) in PV development involving HER isoforms, Src and mTOR kinases. 
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INTRODUCTION 
 
Pemphigus vulgaris (PV) is an autoimmune blistering skin disease characterized by 
suprabasal detachment of epidermal cells known as acantholysis and by anti-epidermal 
autoantibodies (1,2) against the extracellular domain of desmoglein (Dsg) 3 with or 
without anti-Dsg1 (3). There are other non-desmoglein autoantibodies detected in the 
sera of patients with PV (4,5), such as acetylcholine receptors (6), E-cadherin (7) or 
antimitochondrial autoantibodies (8), which have also been implicated in the 
acantholytic process. 
The mechanisms by which these autoantibodies induce acantholysis in PV may be due 
to a direct effect by binding to their target and may be mediated by steric hindrance 
and⁄or by triggering signal transduction pathways in the keratinocyte (9). In this sense, 
several intracellular signalling molecules are triggered in PV after binding of 
autoantibodies to keratinocytes (10–16). Additionally, apoptosis has been suggested to 
play a role in PV (17–22). It is interesting to observe that both apoptosis and 
acantholysis are inhibited when inhibitors for specific intracellular signalling pathways 
are used (16). These observations have led to the concept of apoptolysis (23). In 
addition, it has been established that although apoptosis appears to be a late event and 
may not be indispensable for acantholysis in PV, activation of several members of the 
caspase family takes place in early PV lesions triggering the blistering response 
(22,24). 
Recently, adhesion-linked kinases, such as focal adhesion kinase (FAK), that regulate 
several cellular functions have been receiving increasing attention. FAK is a soluble 
non-receptor tyrosine kinase expressed by almost all tissues and cell types involved in 
cytoskeleton remodelling and in the formation and disassembly of cell adhesion 
structures (25,26). Its presence in mouse epidermis and hair follicle has been detected 
in a pattern that was primarily plasma membrane associated (27). There are several 
tyrosines that could be phosphorylated in FAK, including Y397, Y407, Y576, Y577, 
Y861 and Y925. The residue 397 is the only tyrosine known to be autophosphorylated, 
whereas the others appear to be phosphorylated by Src (28). Although FAK has been 
implicated in promoting an invasive phenotype in some human tumors, it is not yet 
known whether this kinase plays an active role in PV lesions as well. Interestingly, 
Penneys found that FAK protein was mainly overexpressed in acantholytic cells in PV 
and pemphigus foliaceus lesions, but only scarce staining was noted in acantholytic 
cells in Hailey–Hailey disease, and it could not be detected in keratinocytes in 
spongiotic or dyskeratotic processes (29). 
More recently, Chernyavsky et al. (13) have demonstrated that stimulation of a9 
acetylcholine receptor (a9AchR) upregulates the phosphorylation of adhesion 
molecules of the focal adhesions (including FAK) and intercellular junctions 
(including Dsg3) as well as cytokeratins. Inhibition of a9AchR interferes with the 
phosphorylation of adhesion and cytoskeletal proteins and also disrupts cell–cell 
cohesion. In addition, Nguyen et al. (30) described the presence of circulating 
autoantibodies against a9AchR in patients with PV regulating keratinocyte adhesion. 
Currently, in vivo experiments using the pan-HER isoform inhibitors CL-387,785 
(CL) (31), the Src inhibitor PP1 (32), the mammalian target of rapamycin (mTOR) 
inhibitor rapamycin (RP) (33), the pan-caspases inhibitor cpm-VAD-CHO (PCI) (34) 
and the FAK inhibitor PF-573,228 (FI) (35) have been successfully employed to 
explore the involvement of these signalling molecules in several inflammatory 
disorders. 
Our group has already demonstrated a relevant role of HER isoforms, Src, mTOR (16) 
and neural nitric oxide synthase (nNOS) (15) activities in PV lesions by showing that 
specific inhibitors of these molecules are capable of reducing blister formation. 
Additionally, it has also been reported that rapamycin may inhibit IGF-I-induced F-
actin reorganization and phosphorylation of the focal adhesion proteins by the 
disruption of mTOR– raptor complex (36). Therefore, it is tempting to speculate on the 
role of FAK in the detachment of epidermal cells in PV. 
Based on these findings and our previous results, we investigated the role of FAK in 
acantholysis in PV lesions in a mouse model. Herein, we observed for the first time 
that activated FAK takes part in PV acantholysis in a process mediated by changes in 
both Bax and Bcl-2 levels and caspase-9 and caspase-3 activities. We describe a novel 
role of this kinase (FAK) involving HER isoforms, Src and mTOR kinases in PV 
lesions. 
 
 
 
MATERIAL AND METHODS 
 
Human sera 
Our study is based on experiments using IgG fractions isolated from the sera of three 
patients with active mucocutaneous PV and the serum of a healthy donor (NHS). Each 
of these three patients gave their signed consent to use their sera for experimental 
studies. The diagnosis of PV was based on criteria established elsewhere (37). By 
indirect immunofluorescence (IF) using monkey oesophagus, we found that the titre of 
intercellular antibodies for PV sera ranged from 1⁄320 to 1 ⁄640. Immunological 
characterization of PV and NHS sera was included to study the circulating antibodies 
against Dsg1 and Dsg3 using a commercially available enzyme-linked immunosorbent 
assay ELISA kit, following the manufacturer’s recommendations (MBL Naka-Ku, 
Nagoya, Japan). The index value for Dsg1 antibodies for PV sera ranged from 60 to 
189, and that for Dsg3 antibodies from 77 to 173. IgG fractions from the patients with 
PV and from NHS group were prepared as previously described (15,16). 
 
 
Testing IgG pathogenicity using the passive transfer animal model 
All of our experiments were conducted using a mouse model of passive transfer of IgG 
(12). C57BL⁄6J mice were obtained from the Jackson Lab (Bar Harbor, ME, USA). 
The study was performed on 24- to 48-h-old neonatal mice (weighing 1.5–2.0 g) from 
a colony maintained at the Centre of Animal Control at the University of Navarra. IgG 
from all three PV and NHS sera were injected intradermally into neonatal mice (2 
mg⁄g) (n = 3 for each IgG) and evaluated 12 h later for evidence of skin blisters. 
Following examination of the skin for blisters, animals were sacrificed. Clinical 
activity in mice was evaluated [Nikolsky’s sign (Ns)] following the scale used 
elsewhere (16). Skin biopsies from each animal included lesional skin samples for 
conventional histological examination by haematoxylin⁄eosin (H&E) and 
immunohistochemical (IHC) staining and IF techniques. Histological examination was 
evaluated following the scale described elsewhere (16). The present study was 
approved by the Ethics Committee of the University Clinic of Navarra, University of 
Navarra (024⁄08). 
  
 
Pretreatment of mice with inhibitors 
Inhibitors used in our study were administered by a single intradermal injection into 
the back of mice 2 h before PV-IgG administration, as described elsewhere (15,16). 
All inhibitors were purchased from Calbiochem (Darmstadt, Germany). Firstly, each 
inhibitor was dissolved in DMSO and later diluted in PBS before injection into mice 
(n=3 for each inhibitor) at the following doses, based on in vivo studies reported 
elsewhere (16) showing that the inhibitors used are specific for their targets and 
without any side effects in the mice: mTOR activity inhibitor rapamycin (RP), 5 µg⁄g 
body weight (33); Src activity inhibitor PP1, 1 µg⁄g body weight (32); pan-caspase 
inhibitor (cpm-VAD-CHO) (PCI), 1.6 µg⁄g body weight (34). Doses of both pan-HER 
isoform inhibitor CL-387,785 (CL) (10 µg⁄g body weight) and FI PF-573,228 (FI of 
tyrosine phosphorylation in Y397) (dose 5 µg⁄g body weight) were based on the 
specificity studies of Sweeney et al. (31) and Slack-Davis et al. (35), respectively, and 
our studies of effectiveness, morbidity and mortality on mice. In preliminary studies, 
we excluded the effects of dermal manipulation and DMSO by injecting PBS or 
DMSO diluted in PBS. Mice were sacrificed 12 h after PV-IgG fractions injected 
intradermally. 
 
 
IHC staining procedure 
Skin samples from mice pretreated or not with inhibitors and injected with PV-IgG or 
NHS-IgG were obtained for IHC staining as described elsewhere (15,16). A tissue 
microarray was constructed from each specimen in the cohort. Tissue cores of 2 mm in 
size were obtained from paraffin-embedded tissue blocks. Tissue sections were 
incubated with different polyclonal antibodies specific for P-mTOR (Ser2448), diluted 
to 1:50, citrate (Cell Signaling Technology, Beverly, MA, USA); P-Src (Tyr416), 
diluted to 1:100, EDTA (Cell Signaling Technology); FAK Y397, diluted to 1:100, 
Tris (Abcam, Cambridge, UK); FAK Y925, diluted to 1:100, Tris (Bioworld, 
Minneapolis, MN, USA). Negative controls were performed by omission of the 
primary antibodies. Sections were incubated overnight at 4°C with the primary 
antisera. The ratio of stained cells on the basal layer (area of stained basal 
keratinocytes⁄area of total basal keratinocytes) was calculated using image analysis 
software on images acquired with a motorized Axioplan 2ie microscope (Zeiss, 
Oberkochen, Germany), operated through Meta-Morph imaging software (Molecular 
Devices, Downing-town, PA, USA), and fitted with a Zeiss Axio Cam ICc3 camera 
connected to a PC equipped with image-capturing software. Image analysis was 
performed using Matlab Software (The MathWorks Inc, Natick, MA, USA). The 
segmentation algorithm was custom-designed by Dr Ortiz-de-Solorzano’s Morphology 
and Imaging Laboratory (CIMA, University of Navarra) (16). 
 
Measurement of caspase-3 and caspase-9 specific activities  
Caspase-3 and caspase-9 activities were measured in skin biopsies from each animal 
using the Caspase-3 Activity Assay Kit Colorimetric (Sigma-Aldrich, St. Louis, MO, 
USA) and Caspase-9 Activity Assay Kit Colorimetric (Calbiochem, Darmstadt, 
Germany). When indicated, animals were pretreated with inhibitors in the conditions 
described above. Skin biopsies were resuspended in lysis buffer (buffer caspase-3 and 
caspase-9), and caspase-3 and caspase-9 activities were measured following the 
manufacturer’s instructions. The value obtained from the analysis of the NHS samples 
was scored as 1. 
  
 
Preparation of cell lysates and Western blot analysis 
Mouse skin proteins were extracted by homogenization of skin biopsy lysates obtained 
by sonication. Western blot analysis of protein samples was carried out after SDS-
PAGE gels (38) and transferred onto nitrocellulose membranes (GE Healthcare, 
Buckinghamshire, UK). Blots were incubated overnight at 4°C with different 
polyclonal rabbit antibodies, such as anti-Bax and antiBcl-2 (Cell Signaling 
Technology), or monoclonal antibodies, such as anti-β-actin (Sigma-Aldrich). 
Antibodies were diluted according to the manufacturer’s instructions. Membranes 
were washed with T-TBS and incubated for 40 min at room temperature with the 
appropriate secondary antibody diluted 1:10000. After washing, blots were developed 
using the ECL system Super Signal ULTRA kit (Thermo Scientific, Rockford, IL, 
USA), and immunoreactive proteins were visualized on High performance 
chemiluminescence film Amersham (Buckinghamshire, England) HyperfilmTm ECL. 
Densitometric analyses were carried out using a GS-800 calibrated densitometer (Bio-
Rad, Hercules, CA, USA). When necessary, striping treatment was carried out. 
Equivalent loading was confirmed using an antibody against actin. 
 
 
Statistical analysis 
All results are expressed as mean ± SD. Data were analysed using the nonparametric 
Kruskal–Wallis test to determine the differences between all independent groups. 
When significant differences were obtained (P < 0.05), differences between two 
groups were tested using the Mann–Whitney U test. 
 
 
 
RESULTS 
 
Mice injected with PV-IgG show increased levels of FAK phosphorylated on 
tyrosine residues 397 and 925 
Using our animal model, normal human serum (NHS)-IgG injected into mice did not 
induce PV lesions (Fig. 1), whereas injection of PV-IgG reproduced clinical PV 
lesions, with the presence of suprabasal acantholysis (Fig. 1). This clearly 
demonstrates that our mouse model was appropriate for investigating the mechanisms 
implicated in PV. 
Firstly, we studied the presence of P-FAK (Y397⁄925) in the basal layer of the 
epidermis. P-FAK on both Y397⁄925 residues showed a plasma membrane pattern in 
the basal cells of the epidermis in mice injected with NHS-IgG (Figure S1a–c). Also, 
after PV-IgG administration, the expression of P-FAK in these two tyrosine residues 
(397⁄925) revealed an uniform staining throughout the cytoplasm of the basal cells of 
the epidermis only in acantholytic areas, with a higher and significant increased level 
to that found after NHS-IgG administration (P < 0.001) (Figure S1a–c). Non-
acantholytic⁄perilesional areas only showed a peripheral membrane pattern (data not 
shown). 
 
Suprabasal acantholysis induced by PV-IgG was decreased if mice were 
pretreated with FI 
The next step was to determine whether FAK phosphorylation on tyrosine residues 
397 and 925 mighty contribute to the development of PV lesions in our mouse model. 
In other words, we wanted to know whether FAK is only a passive bystander or on the 
contrary it plays a key role in the detachment of cells in PV. Therefore, we 
administered an inhibitor of FAK activity prior to PV-IgG injection to mice and 
compared the results with those observed when mice were injected either with NHS-
IgG or with PV-IgG. None of the mice pretreated with the FI exhibited either clinical 
or histological findings of PV (Fig. 1). Therefore, our results clearly strengthen the 
hypothesis of a highly significant role of FAK activity in the detachment process 
observed in PV lesions.  
 
Pretreatment with inhibitors of mTOR, Src, HER isoforms and pan-caspases 
along with PV-IgG administration in mice may decrease the expression of FAK 
phosphorylated on Y397 and Y925 residues 
After revealing a novel biochemical mechanism for FAK in PV, our next step was to 
understand the underlying mechanism. We decided to investigate whether a 
relationship could be established between FAK, and HER isoforms, Src, mTOR and 
caspases. To answer this question, we administered inhibitors for each of these 
molecules before PV-IgG treatment. P-FAK on tyrosine residues 397 and 925 was 
statistically lower if mice were pretreated with HER isoforms (P < 0.001), Src (P < 
0.001 and P < 0.01, respectively), mTOR (P < 0.001 and P < 0.01, respectively) or 
PCIs (P < 0.001) followed by PV-IgG injection (Figure S1a–c). In addition, P-FAK 
(Y397⁄925) presented a plasma membrane pattern in the basal cells of the epidermis, 
exactly the same as that observed after NHS-IgG injection and completely opposite to 
that observed after the injection of PV-IgG (Figure S1a). Also, clinical PV lesions 
(Nikolsky’s sign) and suprabasal acantholysis in mice were absent when these 
inhibitors were used (data not shown). 
 
 
Inhibition of suprabasal acantholysis of mice pretreated with FI is associated with 
a decrease in the changes in both Bax and Bcl-2 levels, and caspase-9 and 
caspase-3 activities induced by PV-IgG 
After establishing a key role of P-FAK in PV lesions, we wondered how this might 
occur and what mechanisms were acting in this process. Skin samples from mice 
pretreated with FI plus PV-IgG were obtained to test whether this inhibitor might 
affect Bax and Bcl-2 levels measured by western blot assay. The results were 
compared with those obtained in skin samples taken from mice injected only with PV-
IgG or NHS-IgG. When PV-IgG were injected into mice, Bcl-2 and Bax levels were 
significantly lower and higher, respectively, compared with those found in mice 
pretreated with FI (P < 0.001) (Fig. 2a,b). Similar results were found when mice were 
pretreated with HER isoforms (P < 0.001 and P < 0.01, respectively), mTOR (P < 
0.001 and P < 0.01, respectively) and Src inhibitors (P < 0.001) (Fig. 2a,b). 
Subsequently, we decided to investigate whether FI also regulated caspase-3 and 
caspase-9 activities using similar skin samples. Interestingly, we found that the 
significant increase in caspase-3 and caspase-9 activities after PV-IgG injection was 
totally absent when mice were pretreated with the FI (P < 0.001). Identical results were 
obtained when mice were pretreated with HER isoforms (P < 0.001), mTOR (P < 
0.001) or Src (P < 0.001) inhibitors before PV-IgG administration (Fig. 2c). All these 
findings clearly show that FAK, the same as HER isoforms, mTOR and Src (16), may 
contribute to acantholysis in PV lesions by affecting Bcl-2⁄Bax ratio and caspase-3 and 
caspase-9 activities. 
 
 
FI pretreatment reduced the increase in phosphorylated Src and mTOR 
expression induced by PV-IgG in the basal layer of the epidermis 
In the present study, we wondered whether FAK may regulate Src and mTOR in PV. 
Expression levels of P-Src and P-mTOR in the basal layer of the epidermis were 
significantly higher after PV-IgG injection, when compared with those obtained after 
NHS-IgG administration (P < 0.01 and P < 0.001, respectively) (Fig. 3a,b). 
Interestingly, the expression of phosphorylated forms of both kinases was statistically 
lower when mice were pretreated with the FI before PV-IgG administration (P < 
0.001) (Fig. 3a,b). Therefore, FAK may regulate and be regulated by these signalling 
molecules (Src and mTOR) and contribute to orchestrate the acantholysis observed in 
PV lesions. 
 
 
DISCUSSION 
 
Many relevant findings have established that the mechanisms involved in the blistering 
formation in PV are the result of many intracellular molecular events articulated in 
conjunction (multiplehit theory) (6). Thus, several molecules and intracellular 
signalling pathways play an crucial role in the detachment of keratinocytes in PV 
lesions: the phosphatidylinositol-4,5-diphosphate pathway (11), p38 MAP kinase (14), 
nNOS (15), Rho protein (39), HER isoforms (16,21), mTOR (16) and Src kinases 
(5,12,16). 
Several findings have been taken into account before exploring the role of FAK in the 
development of PV lesions: the FAK protein has been found to be increased in 
acantholytic cells in PV (29); also, antibodies against AChR in patients with PV (4) 
upregulate the degree of phosphorylation of FAK (13); FAK plays a role in many 
cellular functions via a cross-talking mechanism with integrins and HER isoforms 
(40); and an important effect of FAK on cytoskeleton may be mediated by mTOR 
kinase activation (31), which plays a role in PV lesions (16). 
Usually, FAK is activated by phosphorylation on different tyrosine residues, either 
through autophosphorylation or through phosphorylation by other kinases such as Src 
kinases (41). Phosphorylated FAK on Y397 interacts with SH2-containing proteins 
including Src, Shc, phosphatidylinositol 3-kinase, growth factor receptor–bound 
protein 7 and phospholipase C (28). This is followed by Src-mediated phosphorylation 
and activation of FAK on residues Y576⁄577 in the kinase domain activation loop (42). 
Src can also phosphorylate FAK on Y407, Y861 and Y925 (43). Our study describes 
for the first time that activated P-FAK (Y397⁄925) plays an important role in the 
detachment of cells in PV lesions. P-FAK expression showed a plasma membrane 
pattern in the basal cells of the epidermis after NHS-IgG administration to mice, such 
as described in the epidermis of non-treated mice (27). However, when mice were 
injected with PV-IgG, P-FAK (Y397⁄925) levels increased showing a diffuse 
cytoplasmic pattern in the basal cells of epidermis. This raises the question of which 
mechanisms are involved in these changes. 
One of the most relevant findings in this study was the inhibition of suprabasal 
acantholysis by pretreatment of PV-IgG injected mice with FI. Caspase activation and 
an increase in the Bax⁄Bcl-2 ratio also seem to be involved in PV development (17–22) 
as suggested in our study. Recently, reorganization of cortical actin filaments has been 
found to be a critical step in PV-IgG-induced keratinocyte dissociation (44). Usually, 
detachment of keratinocytes in PV occurs by the condensation of cytoskeletal 
filaments even before the separation of desmosomes is observed on the lateral sides of 
the basal layer of epidermis (45). mTOR may participate in the development of PV 
lesions (16) by affecting Bcl-2 phosphorylation⁄degradation as it has been described in 
damaged microtubule cells (46). Recently, FAK has been implicated in the 
constellation of pathways that regulate cytoskeletal dynamics (47,48), in a process 
mediated by mTOR upregulation (36). Therefore, our previous observation of the 
abolition of acantholysis induced by PV-IgG in mice pretreated with rapamycin (16), 
along with the present results showing a diminished effect of PVIgG on both the 
Bax⁄Bcl-2 ratio and caspase-3 and caspase-9 activities in the presence of mTOR or FIs, 
strongly supports the role of FAK in acantholysis in PV in our mouse model. This 
hypothesis is supported by the findings of Ravikumar et al. (49), showing that 
rapamycin inhibited apoptosis in a cytochrome c and caspase-3- and caspase-9-
dependent process. 
An important and unresolved issue is to determine whether caspase activation 
contributes to PV development in either an apoptosis-dependent or apoptosis-
independent form. Usually, caspase activation results in the cleavage of several 
substrates implicated in different aspects of apoptosis such as nuclear fragmentation 
and cytoskeletal rearrangement (50). However, other additional roles different from 
apoptosis have been identified for these proteases (51,52). Wang et al. demonstrated 
that caspase-3 and caspase-1 were activated several hours before cell detachment 
induced by PV-IgG in keratinocyte culture (19). Frusic-Zlotkin et al. obtained similar 
results measuring caspase-8 and caspase-3 (25). Also, our present and previous results 
and several other reports confirm that pan-caspase inhibitor may abolish PV and 
pemphigus foliaceus acantholysis (16,53). Recently, Cirillo et al. (54) have observed 
that caspases may be activated as an early pathogenic event in PV acantholysis, 
whereas apoptosis is only a late finding not necessary for acantholysis. These authors 
conclude that although apoptosis may be observed in PV, the pathogenic event leading 
to acantholysis is the activation of caspases. Several research groups have reported a 
direct effect of caspases on FAK mainly caspase-3, caspase-6 and caspase-7 and a 
cleavage of this kinase during apoptosis (55,56). In the present study, we have shown 
that during PV development, the location of FAK in the cell is modified by caspases 
probably due to the fragmentation of itself and other cytoskeletal proteins. On the 
other hand, the blocking effect of pan-caspase inhibitor on PV-IgG induced FAK 
phosphorylation seems to indicate the existence of a positive loop that would 
contribute to the progression of the acantholytic process (Fig. 4). This positive loop 
would be generated by the activation of some protein kinase by caspases (Fig. 4) such 
as has been described in other systems (57). One of the kinases activated by caspases 
is MEKK1, which is involved in the activation of p38, an apoptotic kinase that 
participates in PV acantholysis (14). In this sense, activation of caspases might 
contribute to the disruption of the desmosome and disintegration of the intermediate 
filament system (58,59). 
Another relevant issue is the mechanism implicated in FAK activation in PV lesions 
and its relationship with other kinases. Our results indicate a relationship between 
HER isoforms, Src kinase and FAK, showing a significant decreased expression of P-
FAK (Y397⁄925) in PV-IgG-injected mice by pretreatment with Src and HER 
inhibitors. These findings may be explained taking into account that FAK may be 
upregulated by recruitment and interaction through its unique FAK N-terminal domain 
with P-EGFR (40), which is increased in mice treated with PV-IgG (16). In addition, 
upon the stimulation of EGFR, recruited FAK is auto- or transphosphorylated at Y397 
generating a docking site for Src. Because phosphorylation by Src represents a relevant 
step to induce the activation of FAK, as has been reported above (28,41), Src inhibitor 
PP1 may help to abolish acantholysis, at least in part, by the inhibition of FAK 
activation. Therefore, our previous findings showing the absence of clinical and 
histological lesions in mice pretreated with PP1 and injected with PV-IgG (12,16) may 
be explained, at least in part, by the inhibition of Src-mediated activation of FAK (Fig. 
4). Indeed, the effect of FAK on Src phosphorylation degree could be explained by the 
capacity of P-FAK (Y397) to recruit and activate Src (28). 
Some authors suggest that mTOR might switch its kinase activity to transmit survival 
or death signals (60). Also, it has been described that inhibition of PI3K⁄Akt signalling 
increases death signals initiated by damaged microtubules leading to the 
phosphorylation⁄degradation of Bcl-2 by mTOR (46). In this way, the absence of Akt 
in the basal cells of the epidermis (61) would increase the amount of mTOR that may 
be phosphorylated and activated by Src (62) leading to Bcl-2 
phosphorylation⁄degradation and subsequent caspase activation in mice injected with 
PV-IgG. 
  
In conclusion, in PV acantholysis, FAK, Src and mTOR seem to be activated as a 
result of HER isoform stimulation in a molecular platform possibly generated by 
adapter and scaffold proteins that provide multiple docking sites for an array of 
signalling and structural proteins. Some of the proteins in this platform may receive 
information from Dsg or non-Dsg autoantigen receptors in PV (4,5) and hence 
modulate the acantholytic response. As this study has been carried out in a mouse 
model, future investigations using skin⁄mucosa from the patients with PV are needed in 
order to analyse the role of these signalling molecules in human PV. However, the 
successful use of mTOR inhibitors in patients with PV (63,64) underlines the 
relevance of our findings. Indeed, better insight into the signalling cascades involved 
in PV acantholysis might expand the number of therapeutic options for this blistering 
disease. 
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Figure 1. Clinical and histological findings after NHS-IgG, PV-IgG, or FAK inhibitor 
(FI) plus PV-IgG injections. Mice were injected on the back (dotted area of skin) with 
NHS-IgG or PV-IgG. When NHS-IgG were administrated to mice, no clinical or 
histological findings (acantholysis) of PV were found. However, if mice were treated 
with PV-IgG, detachment of skin (Nikolsky’s sign ) was observed and suprabasal 
acantholysis was detected (↓). Those mice pretreated with FI prior to PV-
IgG injection did 
dhesion kinase; N
not show either clinical or histological PV lesions. FAK, focal 
HS, normal human serum; PV, pemphigus vulgaris; (1), PV-IgG 
ersus NHS-IgG; (2), FI plus PV-IgG versus PV-IgG; bars = 50 lm. 
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< 0.001; bars = 50 
 
 
Figure 2. Mice injected with PV-IgG showed higher and lower levels of Bax and Bcl-
2 respectively, and higher caspase-3 and caspase-9 activities, compared with mice 
injected with either NHS-IgG or mice pretreated with inhibitors before PV-IgG 
administration. (a) Levels of Bax and Bcl-2 analysed by western blotting, (b) 
quantitation of blots and (c) quantitation of caspase-3 and caspase-9 activities, when 
mice were treated with NHS-IgG, and PV-IgG only or pretreated with inhibitors. NHS, 
normal human serum; PV, pemphigus vulgaris; HER isoforms (CL), Src (PP1), mTOR 
(RP), FAK (FI) and pan-caspases (PCI) inhibitors; (1), PV-IgG versus NHS-I
several inhibitors plus PV-IgG versus PV-IgG; **P < 0.01; ***P 
lm. The results are expressed as mean ± SD of nine independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
several inhibitors plus PV-IgG versus PV-IgG; **P < 0.01; 
**P < 0.001; bars = 50 lm. The results are expressed as mean ± SD of nine 
dependent experiments. 
 
 
Figure 3. Mice injected with PV-IgG showed a higher expression of both P-Src and P-
mTOR kinases in the basal cells of the epidermis when compared with those injected 
with either NHS-IgG or pretreated with focal adhesion kinase (FAK) inhibitor before 
PV-IgG injection. (a) P-Src and P-mTOR immunohistochemistry detection after NHS-
IgG, PV-IgG or FI plus PV-IgG administration (↓) and (b) quantitation of 
immunohistochemistry. FI, FAK inhibitor; PV, pemphigus vulgaris; NHS, normal 
human serum; P, phosphorylated; mTOR, mammalian target of rapamycin; (1), PV-
IgG versus NHS-IgG; (2), 
*
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promote the progression of the acantholytic process. Mutual effects between 
AK and Src, mTOR or caspases would also contribute to achieve acantholysis in PV 
sions. 
 
 
 
 
Figure 4. Hypothetical connection between HER isoforms, focal adhesion kinase 
(FAK), Src, mammalian target of rapamycin (mTOR) and caspases during pemphigus 
vulgaris (PV) acantholysis in the basal layer of the epidermis. Our present and 
previous findings (16) indicate that FAK, Src and mTOR may be activated as a result 
of HER isoforms’ stimulation. In addition, mTOR may increase caspase activity by 
inducing phosphorylation ⁄ degradation of Bcl-2. In turn, a positive loop might be 
generated by caspases acting on FAK and other kinases, and cytoskeletal proteins in 
order to 
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